Test Catalog

Test Id : AATHR

Thrombophilia Profile, Plasma and Whole Blood

Useful For
Suggests clinical disorders or settings where the test may be helpful

Evaluating patients with thrombosis or hypercoagulability states

 

Detecting a lupus-like anticoagulant; dysfibrinogenemia; disseminated intravascular coagulation/intravascular coagulation and fibrinolysis

 

Detecting a deficiency of antithrombin, protein C, or protein S

 

Detecting activated protein C resistance (and the factor V Leiden [p.Arg534Gln, historically known as R506Q] variant if indicated)

 

Detecting the prothrombin F2 c.*97G>A variant (historically known as G20210A)

Profile Information
A profile is a group of laboratory tests that are ordered and performed together under a single Mayo Test ID. Profile information lists the test performed, inclusive of the test fee, when a profile is ordered and includes reporting names and individual availability.

Test Id Reporting Name Available Separately Always Performed
AATHI Thrombophilia Interpretation No Yes
PTSC Prothrombin Time (PT), P Yes, (order PTTP) Yes
APTSC Activated Partial Thrombopl Time, P Yes, (order APTTP) Yes
DRV1 Dilute Russells Viper Venom Time, P Yes, (order DRVI1) Yes
TTSC Thrombin Time (Bovine), P Yes Yes
CLFIB Fibrinogen, Clauss, P Yes, (order FIBTP) Yes
DIMER D-Dimer, P Yes, (order DDITT) Yes
ATTF Antithrombin Activity, P Yes Yes
CFX Protein C Activity, P Yes Yes
PSF Protein S Ag, Free, P Yes, (order PSTF) Yes
APCRV Activated Protein Resistance V, P Yes Yes
PTNT Prothrombin G20210A Mutation, B Yes Yes

Reflex Tests
Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests.

Test Id Reporting Name Available Separately Always Performed
ATTI Antithrombin Antigen, P Yes No
FACTV Coag Factor V Assay, P Yes No
F_7 Coag Factor VII Assay, P Yes No
F_9 Coag Factor IX Assay, P Yes No
F_10 Coag Factor X Assay, P Yes No
F_11 Coag Factor XI Assay, P Yes No
F_12 Coag Factor XII Assay, P Yes No
F8A Coag Factor VIII Activity Assay, P Yes No
RTSC Reptilase Time, P Yes No
F_2 Coag Factor II Assay, P Yes No
PCAG Protein C Ag, P Yes No
F5DNA Factor V Leiden (R506Q) Mutation, B Yes No
PNP Platelet Neutralization Procedure No No
PTMSC PT Mix 1:1 No No
APMSC APTT Mix 1:1 No No
PST Protein S Ag, Total, P No No
STACL Staclot LA, P No No
DRV2 DRVVT Mix No No
DRV3 DRVVT Confirmation No No
S_FX Protein S Activity, P Yes No
SOLFM Soluble Fibrin Monomer No No
PTFIB PT-Fibrinogen, P No No

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Initial testing includes: prothrombin time (PT); activated partial thromboplastin time (aPTT); dilute Russell viper venom time (dRVVT); thrombin time (bovine); fibrinogen; D-dimer; antithrombin activity; protein C activity; protein S antigen, free;  prothrombin G20210A variant; activated protein resistance V; and thrombophilia interpretation.

 

If the PT is >13.9 seconds, then the PT mixing study will be performed at an additional charge.

 

If the aPTT is > or =38 seconds, then the aPTT mixing study will be performed at an additional charge.

 

If the aPTT mix result is > or =38 seconds and thrombin time is <35.0 seconds (no evidence of heparin), then the platelet neutralization procedure will be performed at an additional charge.

 

If the dRVVT ratio is > or =1.20, then the dRVVT mixing study and dRVVT confirmation will be performed at an additional charge.

 

If the thrombin time is > or =25.0 seconds, then the reptilase time will be performed at an additional charge.

 

If the fibrinogen result is <150 mg/dL or clinically indicated, then PT-fibrinogen will be performed at an additional charge.

 

If the D-dimer result is >500 ng/mL fibrinogen equivalent units (FEU), then soluble fibrin monomer testing will be performed at an additional charge.

 

If the free protein S antigen result is <65% for males and females > or =50 years of age and <50% for females <50 years of age, then the total protein S antigen test will be performed at an additional charge.

 

If the protein C activity is <70% with no evidence for an acquired decrease in protein C activity, then protein C antigen testing may be performed at an additional charge.

 

If the antithrombin activity is <80% with no evidence of an acquired decrease in antithrombin activity, then antithrombin antigen testing will be performed at an additional charge.

 

If the activated protein C resistance (APC) ratio is <2.3 or the baseline APC aPTT is prolonged, then factor V Leiden (R506Q) variant analysis will be performed at an additional charge.

 

If appropriate, protein S activity, coagulation factor assays, or Staclot LA will be performed at an additional charge to clarify significant abnormalities in the screen test results.

 

See Thrombophilia Profile in Special Instructions.

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Method Name
A short description of the method used to perform the test

PTSC, APTSC, DRV1, TTSC, APCRV: Optical Clot-Based

CLFIB: Clauss

DIMER, PSF: Latex Immunoassay (LIA)

ATTF, CFX: Chromogenic Assay

PTNT: Direct Mutation Analysis

NY State Available
Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name
Lists a shorter or abbreviated version of the Published Name for a test

Thrombophilia Prof

Aliases
Lists additional common names for a test, as an aid in searching

Coag

Hypercoagulability

Thrombophilia Profile

Thrombosis

Clotting

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Initial testing includes: prothrombin time (PT); activated partial thromboplastin time (aPTT); dilute Russell viper venom time (dRVVT); thrombin time (bovine); fibrinogen; D-dimer; antithrombin activity; protein C activity; protein S antigen, free;  prothrombin G20210A variant; activated protein resistance V; and thrombophilia interpretation.

 

If the PT is >13.9 seconds, then the PT mixing study will be performed at an additional charge.

 

If the aPTT is > or =38 seconds, then the aPTT mixing study will be performed at an additional charge.

 

If the aPTT mix result is > or =38 seconds and thrombin time is <35.0 seconds (no evidence of heparin), then the platelet neutralization procedure will be performed at an additional charge.

 

If the dRVVT ratio is > or =1.20, then the dRVVT mixing study and dRVVT confirmation will be performed at an additional charge.

 

If the thrombin time is > or =25.0 seconds, then the reptilase time will be performed at an additional charge.

 

If the fibrinogen result is <150 mg/dL or clinically indicated, then PT-fibrinogen will be performed at an additional charge.

 

If the D-dimer result is >500 ng/mL fibrinogen equivalent units (FEU), then soluble fibrin monomer testing will be performed at an additional charge.

 

If the free protein S antigen result is <65% for males and females > or =50 years of age and <50% for females <50 years of age, then the total protein S antigen test will be performed at an additional charge.

 

If the protein C activity is <70% with no evidence for an acquired decrease in protein C activity, then protein C antigen testing may be performed at an additional charge.

 

If the antithrombin activity is <80% with no evidence of an acquired decrease in antithrombin activity, then antithrombin antigen testing will be performed at an additional charge.

 

If the activated protein C resistance (APC) ratio is <2.3 or the baseline APC aPTT is prolonged, then factor V Leiden (R506Q) variant analysis will be performed at an additional charge.

 

If appropriate, protein S activity, coagulation factor assays, or Staclot LA will be performed at an additional charge to clarify significant abnormalities in the screen test results.

 

See Thrombophilia Profile in Special Instructions.

Specimen Type
Describes the specimen type validated for testing

Plasma Na Cit

Whole blood

Ordering Guidance

Multiple coagulation profile tests are available. See Coagulation Profile Comparison in Special Instructions for testing that is performed with each profile.

Shipping Instructions

Send all specimens in the same shipping container.

Specimen Required
Defines the optimal specimen required to perform the test and the preferred volume to complete testing

Both blood and plasma are required.

 

Patient Preparation:

1. Patient should not be receiving Coumadin (warfarin), heparin, direct thrombin inhibitors (argatroban, dabigatran), or direct factor Xa inhibitors (apixaban, rivaroxaban, and edoxaban).

2. Specimen must be collected prior to initiation of anticoagulants and thrombolytic therapy.

3. If patient has been recently transfused, it is best to perform this study pretransfusion, if possible.

 

Specimen Type: Whole blood

Container/Tube:

Preferred: Lavender top (EDTA)

Acceptable: Yellow top (ACD), light-blue top (3.2% sodium citrate)

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send specimen in original tube. Do not aliquot.

3. Label specimen as whole blood.

 

Specimen Type: Platelet-poor plasma

Collection Container/Tube: Light-blue top (3.2% sodium citrate)

Submission Container/Tube: Plastic vial (polypropylene preferred)

Specimen Volume: 5 mL in 5 plastic vials; each containing 1 mL

Collection Instructions:

1. Specimen must be collected prior to factor replacement therapy.

2. For complete instructions, see Coagulation Guidelines for Specimen Handling and Processing in Special Instructions.

3. Centrifuge, transfer all plasma into a plastic vial, and centrifuge plasma again.

4. Aliquot plasma (1-2 mL per aliquot) into 5 separate plastic vials leaving 0.25 mL in the bottom of centrifuged vial.

5. Freeze plasma immediately (no longer than 4 hours after collection) at -20 degrees C or, ideally, < or =-40 degrees C.

Additional Information:

1. Double-centrifuged specimen is critical for accurate results as platelet contamination may cause spurious results.

2. If priority specimen, mark request form, give reason, and request a call-back.

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Forms

1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available in Special Instructions:

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing-Spanish (T826)

2. Coagulation Patient Information (T675) in Special Instructions

3. If not ordering electronically, complete, print, and send a Coagulation Test Request (T753) with the specimen.

Specimen Minimum Volume
Defines the amount of sample necessary to provide a clinically relevant result as determined by the Testing Laboratory

Plasma: 5 mL in 5 plastic vials each containing 1 mL

Whole Blood: 1 mL

Reject Due To
Identifies specimen types and conditions that may cause the specimen to be rejected

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Specimen Stability Information
Provides a description of the temperatures required to transport a specimen to the performing laboratory, alternate acceptable temperatures are also included

Specimen Type Temperature Time Special Container
Plasma Na Cit Frozen (preferred) 14 days
Whole blood Ambient (preferred) 14 days
Frozen 14 days
Refrigerated 14 days

Useful For
Suggests clinical disorders or settings where the test may be helpful

Evaluating patients with thrombosis or hypercoagulability states

 

Detecting a lupus-like anticoagulant; dysfibrinogenemia; disseminated intravascular coagulation/intravascular coagulation and fibrinolysis

 

Detecting a deficiency of antithrombin, protein C, or protein S

 

Detecting activated protein C resistance (and the factor V Leiden [p.Arg534Gln, historically known as R506Q] variant if indicated)

 

Detecting the prothrombin F2 c.*97G>A variant (historically known as G20210A)

Testing Algorithm
Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Initial testing includes: prothrombin time (PT); activated partial thromboplastin time (aPTT); dilute Russell viper venom time (dRVVT); thrombin time (bovine); fibrinogen; D-dimer; antithrombin activity; protein C activity; protein S antigen, free;  prothrombin G20210A variant; activated protein resistance V; and thrombophilia interpretation.

 

If the PT is >13.9 seconds, then the PT mixing study will be performed at an additional charge.

 

If the aPTT is > or =38 seconds, then the aPTT mixing study will be performed at an additional charge.

 

If the aPTT mix result is > or =38 seconds and thrombin time is <35.0 seconds (no evidence of heparin), then the platelet neutralization procedure will be performed at an additional charge.

 

If the dRVVT ratio is > or =1.20, then the dRVVT mixing study and dRVVT confirmation will be performed at an additional charge.

 

If the thrombin time is > or =25.0 seconds, then the reptilase time will be performed at an additional charge.

 

If the fibrinogen result is <150 mg/dL or clinically indicated, then PT-fibrinogen will be performed at an additional charge.

 

If the D-dimer result is >500 ng/mL fibrinogen equivalent units (FEU), then soluble fibrin monomer testing will be performed at an additional charge.

 

If the free protein S antigen result is <65% for males and females > or =50 years of age and <50% for females <50 years of age, then the total protein S antigen test will be performed at an additional charge.

 

If the protein C activity is <70% with no evidence for an acquired decrease in protein C activity, then protein C antigen testing may be performed at an additional charge.

 

If the antithrombin activity is <80% with no evidence of an acquired decrease in antithrombin activity, then antithrombin antigen testing will be performed at an additional charge.

 

If the activated protein C resistance (APC) ratio is <2.3 or the baseline APC aPTT is prolonged, then factor V Leiden (R506Q) variant analysis will be performed at an additional charge.

 

If appropriate, protein S activity, coagulation factor assays, or Staclot LA will be performed at an additional charge to clarify significant abnormalities in the screen test results.

 

See Thrombophilia Profile in Special Instructions.

Clinical Information
Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Thrombophilia is defined as an acquired or familial disorder associated with thrombosis. The clinical presentation of an underlying thrombophilia predominantly includes venous thromboembolism (deep vein thrombosis, pulmonary embolism, superficial vein thrombosis). Other manifestations that have been linked to thrombophilia include recurrent miscarriage and complications of pregnancy (eg, severe preeclampsia, abruptio placentae, intrauterine growth restriction, stillbirth). The current thrombophilia does not predict for arterial thrombosis. Demographic or environmental exposures that compound the risk of venous thromboembolism among persons with a thrombophilia include increasing age, male gender, obesity, surgery, trauma, hospitalization for medical illness, malignant neoplasm, prolonged immobility during travel (eg, prolonged airplane travel), oral contraceptive use, estrogen therapy (both oral and transdermal), tamoxifen and raloxifene therapy, and infertility drugs. Central venous catheters and transvenous pacemaker wires increase the risk for upper extremity deep vein thrombosis; this risk is unrelated to thrombophilia.

 

Inherited thrombophilias include:

-Deficiency due to reduced plasma protein level or dysfunctional protein of:

-Antithrombin

-Protein C

-Protein S

-Dysfibrinogenemias (rare)

-Activated protein C resistance due to the factor V Leiden variant (F5 c.1601G>A; p.Arg534Gln, historically known as R506Q)

-Prothrombin F2 c.*97G>A variant (historically known as G20210A)

 

Acquired thrombophilias include a lupus-like anticoagulant (antiphospholipid antibodies) and disseminated intravascular coagulation/intravascular coagulation and fibrinolysis (DIC/ICF). DIC/ICF may cause thrombotic as well as hemorrhagic events. Positive tests for DIC/ICF can also occur as consequences of thrombosis.

 

Acquired deficiencies of fibrinogen, protein C, protein S, and antithrombin may be found in conjunction with liver disease (they are produced by the liver) or DIC/ICF and are of uncertain significance with respect to thrombosis risk.

 

Acquired deficiencies of protein C and protein S are also found in patients with liver disease who are being treated with oral anticoagulants (eg, warfarin, Coumadin), since both of these proteins are dependent upon the action of vitamin K for normal function.

 

Acquired protein S deficiency also occurs in thrombotic thrombocytopenic purpura, pregnancy or estrogen therapy, nephrotic syndrome, and sickle cell anemia. In acute illness, the level of acute-phase reactants rise (including C4b binding protein, which binds and inactivates protein S in the plasma) and the portion of bound protein S also rises leaving a lower proportion of free protein S. The significance of acquired protein S deficiency with respect to thrombosis risk is unknown.

Reference Values
Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

An interpretive report will be provided.

Interpretation
Provides information to assist in interpretation of the test results

An interpretive report will be provided.

Cautions
Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances

To obtain the most useful information, this testing is best performed in medically-stable patients who are not receiving oral vitamin K inhibitor (eg, warfarin, Coumadin), heparin, low-molecular-weight heparin, hirudin (Refludan), argatroban, fibrinolytic agents (eg, streptokinase, tissue plasminogen activator), or platelet GPIIbIIIa (alpha IIb beta3) inhibitors (abxicimab [ReoPro], tirofiban, aggrastat). However, useful information can be obtained in patients receiving anticoagulation therapy.

Clinical Reference
Recommendations for in-depth reading of a clinical nature

1. Pengo V, Tripodi A, Reber G, et al: Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009;7(10):1737-1740. doi: 10.1111/j.1538-7836.2009.03555.x

2. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M, British Committee for Standards in Haematology: Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haemotol. 2012;157(1):47-58. doi: 10.1111/j.1365-2141.2012.09037.x

3. Clinical and Laboratory Standards Institute (CLSI). Laboratory Testing for the Lupus Anticoagulant; Approved Guideline. CLSI document H60-A. Clinical Laboratory Standards Institute; 2014

Special Instructions
Library of PDFs including pertinent information and forms related to the test

Method Description
Describes how the test is performed and provides a method-specific reference

Prothrombin Time:

The prothrombin time (PT) assay is performed on the Instrumentation Laboratory ACL TOP. Patient plasma is incubated and combined with a PT reagent containing recombinant human tissue factor, synthetic phospholipids, calcium chloride, polybrene, and buffer. The tissue thromboplastin-factor VII/VIIa complex activates factor X. Activated factor X (factor Xa) forms a complex with factor Va, calcium, and phospholipid to activate factor II (prothrombin) to thrombin. Thrombin then acts on fibrinogen (factor I) to form fibrin which clots, the time to clot formation is measured optically using a wavelength of 671 nm providing the assay endpoint (the "prothrombin time").(Package insert: HemosIL RecombiPlasTin 2G. Instrumentation Laboratory Company; R4, 03/2019)

 

Activated Partial Thromboplastin Time:

The activated partial thromboplastin time (aPTT) assay is performed on the Instrumentation Laboratory ACL TOP. Patient plasma is combined and incubated with an aPTT reagent containing phospholipid, a negatively charged contact factor activator, and buffer. After a specified incubation time, calcium is added to trigger the coagulation process in the mixture. Subsequently, the time to clot formation is measured optically using a wavelength of 671 nm. Mixing studies (see APMSC / Activated Partial Thromboplastin Time [APTT] Mix 1:1, Plasma) using normal pooled plasma are performed in the Special Coagulation Laboratory on samples with a prolonged aPTT, to assist in discriminating between factor deficiency states and coagulation inhibitors, unless further testing is not indicated.(Package insert: HemosIL SynthASil. Instrumentation Laboratory Company; R11, 06/2017)

 

Dilute Russell Viper Venom Time:

The dilute Russell viper venom time (dRVVT) screening assay is performed on the Instrumentation Laboratory ACL TOP. Patient plasma is incubated for a specified time and then combined with a dRVVT screening reagent containing Russell viper venom, phospholipids, heparin neutralizing agents, calcium, buffers and stabilizers to trigger the coagulation process. Subsequently, the time to clot formation is measured optically using a wavelength of 671 nm. The patient dRVVT screening clotting time is normalized by dividing the patient result by the mean dRVVT screening clotting time of normal pooled plasma to yield a ratio (dRVVT screen ratio).(Package insert: LA CHECK DRVVT. Precision Biologic;  R14, 03/2012)

 

Thrombin Time:

The thrombin time assay is performed on the Instrumentation Laboratory ACL TOP. Patient plasma is combined with a bovine thrombin reagent containing bovine albumin, calcium chloride, and buffer immediately triggering the coagulation process in the mixture. Time to clot formation is measured optically using a wavelength of 671 nm.(Package insert: HemosIL Thrombin Time. Instrumentation Laboratory Company; R1 12/2018)

 

Fibrinogen:

The Clauss fibrinogen assay is performed using the HemosIL Fibrinogen-C kit on the Instrumentation Laboratory ACL TOP. Patient plasma, containing fibrinogen, is mixed with reagent containing excess thrombin. The excess thrombin converts the fibrinogen in the patient plasma to fibrin. The amount of time it takes to form a clot is inversely proportional to the amount of fibrinogen present in the patient plasma.(Package insert: HemosIL Fibrinogen-C. Instrumentation Laboratory Company; R7, 06/2017)

 

D-Dimer:

The D-dimer assay is performed using the HemosIL D-Dimer HS 500 kit on the Instrumentation Laboratory ACL TOP instrument. D-dimer is assayed in plasma by adding polystyrene latex particles coated with monoclonal antibodies specific for D-dimer domain. The latex particles agglutinate in the presence of soluble fibrin degradation products (FDP) containing the D-dimer domain. The degree of agglutination is directly proportional to the concentration of D-dimer in the sample and is determined by measuring the decrease of transmitted light caused by the aggregates (turbidimetric immunoassay).(Package insert: HemosIL D-Dimer HS 500. Instrumentation Laboratory Company; R6 04/2018)

 

Antithrombin Activity:

This assay is performed using the HemosIL Liquid Antithrombin Kit on the Instrumentation Laboratory ACL TOP instrument. Patient plasma, containing antithrombin, is mixed and incubated with reagent containing factor Xa and excess heparin. Factor Xa activity in the reagent is rapidly inhibited by antithrombin. Residual factor Xa activity is then measured using an amidolytic activity assay. This occurs when residual factor Xa lyses chromogenic substrate S-2765 (N-alpha-Z-D-Arg-Gly-Arg-pNA 2HCI) and subsequently releases pNA (detected at 405 nm) in a level that is inversely proportional to the amount of antithrombin in the sample. This method is based on inhibition of factor Xa and, therefore, only higher amounts of heparin cofactor II, alpha-2-macroglobulin, or alpha-1-antitrypsin will influence the assay.(Package insert: HemosIL Liquid Antithrombin. Instrumentation Laboratory Company; R8 06/2017)

 

Protein C Activity:

This assay is performed using the HemosIL Protein C kit on the Instrumentation Laboratory ACL TOP. Protein C in plasma is activated by a specific enzyme (Protein C activator) from copperhead snake venom (Agkistrodon contortrix contortrix). The amount of activated protein C is determined by the rate of hydrolysis of the chromogenic substrate, S-2366 (pyroGlu Pro-Arg-pNA-HCL). The pNA release is measured kinetically at 405 nm and is directly proportional to the protein C level in the plasma.(Package insert: HemosIL Protein C. Instrumentation Laboratory; R8 06/2017)

 

Protein S Free:

This assay is performed using the HemosIL Free Protein S kit on the Instrumentation Laboratory ACL TOP. The assay uses latex immunoassay methodology to determine the presence of free protein S. It consists of 2 latex reagents, one being latex particles coated with purified human C4BP and the other is latex particles coated with a monoclonal antibody directed against human protein S. Patient plasma is combined with the purified C4BP that reacts with a high affinity for free protein S in the patient plasma. The free protein S adsorbed on the C4BP latex triggers the agglutination reaction with the second latex reagent. The aggregates form diameters greater than the wavelength of the light (405nm) passing through, causing absorption of the light. This change in absorption is measured over time and reported as delta optical density (OD). The increase in absorption is proportional to the concentration of free protein S antigen present in the patient plasma. (Package insert: HemosIL Free Protein S. Instrumentation Laboratory; R15 04/2019)

 

Activated Protein C Resistance:

This assay is performed using the HemosIL Factor V Leiden (APC Resistance V) Kit on the Instrumentation Laboratory ACL TOP instrument. The method uses a modified activated partial thromboplastin time (APTT) test to detect activated protein C (APC) resistance. The plasma specimen is prediluted in factor V-deficient plasma. Then the APTT test is performed by incubating patient plasma with a standardized amount of platelet-like phospholipids and activator of the contact factors of the intrinsic coagulation pathway, followed by recalcification of plasma and measurement of clotting time. The ratio of the APTT test with and without added APC is reported as the APC resistance (or sensitivity) ratio.(Package insert: HemosIL Factor V Leiden [APC Resistance V]. Instrumentation Laboratory Company; R12 11/2017)

 

Prothrombin G20210A Variant:  

An allelic discrimination assay is set up using TaqMan chemistry. End-products are analyzed using the Roche LightCycler 480 System for genotype detection.(Package insert: TaqMan SNP Genotyping Assays., Applied Biosystems; 2014)

PDF Report
Indicates whether the report includes an additional document with charts, images or other enriched information

No

Day(s) Performed
Outlines the days the test is performed. This field reflects the day that the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time before the test is performed. Some tests are listed as continuously performed, which means that assays are performed multiple times during the day.

PTSC, APTSC, DRV1, CLFIB, DIMER, CFX, PSF, APCRV: Monday through Friday

TTSC, ATTF: Monday through Saturday

PTNT: Weekly

Report Available
The interval of time (receipt of sample at Mayo Clinic Laboratories to results available) taking into account standard setup days and weekends. The first day is the time that it typically takes for a result to be available. The last day is the time it might take, accounting for any necessary repeated testing.

4 to 7 days

Specimen Retention Time
Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

Plasma: 7 days; Whole blood: 2 weeks

Performing Laboratory Location
Indicates the location of the laboratory that performs the test

Rochester

Fees
Several factors determine the fee charged to perform a test. Contact your U.S. or International Regional Manager for information about establishing a fee schedule or to learn more about resources to optimize test selection.

  • Authorized users can sign in to Test Prices for detailed fee information.
  • Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
  • Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR) product.

See Individual Test IDs

CPT Code Information
Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Clinic Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.

CPT codes are provided by the performing laboratory.

81240-F2 (prothrombin, coagulation factor II) (eg, hereditary hypercoagulability) gene analysis, 20210G->A variant

85300-AT activity

85303-Protein C activity

85306-Protein S antigen, free

85307-Activated protein resistance V

85379-D-Dimer

85384-Fibrinogen

85390-26-Special coagulation interpretation

85610-PT

85613-DRVVT

85670-Thrombin time

85730-APTT

81241-F5 (coagulation factor V) (eg, hereditary hypercoagulability) gene analysis, Leiden variant (if appropriate)

85210-Factor II (if appropriate)

85220-Factor V (if appropriate)

85230-Factor VII (if appropriate)

85240-Factor VIII (if appropriate)

85250-Factor IX (if appropriate)

85260-Factor X (if appropriate)

85270-Factor XI (if appropriate)

85280-Factor XII (if appropriate)

85301-Antithrombin antigen (if appropriate)

85302-Protein C antigen (if appropriate)

85305-Protein S antigen, total (if appropriate)

85306-Protein S activity (if appropriate)

85366-Soluble fibrin monomer (if appropriate)

85385-PT-Fibrinogen (if appropriate)

85597-Platelet neutralization for lupus inhibitor (if appropriate)

85598-Staclot LA (if appropriate)

85611-PT mix 1:1 (if appropriate)

85613-DRVVT mix (if appropriate)

85613-DRVVT confirmation (if appropriate)

85635-Reptilase time (if appropriate)

85732-APTT mix 1:1 (if appropriate)

LOINC® Information
Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the order and results codes of this test. LOINC values are provided by the performing laboratory.

Test Id Test Order Name Order LOINC Value
AATHR Thrombophilia Prof 98125-8
Result Id Test Result Name Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
ATTF Antithrombin Activity, P 27811-9
CFX Protein C Activity, P 27818-4
PSF Protein S Ag, Free, P 27821-8
APCR APCRV Ratio 13590-5
INT55 Interpretation 48591-2
21803 Prothrombin G20210A Mutation, B 24475-6
21804 PTNT Interpretation 69049-5
21806 PTNT Reviewed By 18771-6
APTSC Activated Partial Thrombopl Time, P 14979-9
CLFIB Fibrinogen, Clauss, P 48664-7
TTSC Thrombin Time (Bovine), P 46717-5
DIMER D-Dimer, P 48067-3
INRSC INR 6301-6
PTSEC Prothrombin Time (PT), P 5902-2
603184 Thrombophilia Interpretation 69049-5
603325 Reviewed by 18771-6
RVR1 DRVVT Screen Ratio 15359-3

Test Setup Resources

Setup Files
Test setup information contains test file definition details to support order and result interfacing between Mayo Clinic Laboratories and your Laboratory Information System.

Excel | Pdf

Sample Reports
Normal and Abnormal sample reports are provided as references for report appearance.

Normal Reports | Abnormal Reports

SI Sample Reports
International System (SI) of Unit reports are provided for a limited number of tests. These reports are intended for international account use and are only available through MayoLINK accounts that have been defined to receive them.

SI Normal Reports | SI Abnormal Reports